Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors.

ABSTRACT:

Introduction

To evaluate the impact of Sars-Cov-2 infection on mortality and immune checkpoint inhibitor (ICI) toxicity in patients with cancer receiving ICIs compared to those not receiving ICIs.

Methods

We conducted a retrospective matched cohort study of 25 patients receiving ICIs within 1 year of coronavirus disease 2019 (COVID-19) diagnosis between March 20, 2020, and June 3, 2020, at the Dana-Farber Cancer Institute/Mass General Brigham. Cases were matched 1:1 with controls based on age, sex, and anticancer therapy within the prior 6 months.

Results

Seven of 25 (28%) patients receiving ICIs died from COVID-19 as compared with nine of 25 (36%) controls. Through multivariable analysis adjusting for age, sex, and anticancer therapy, ICI use was not associated with

SUBMITTER: Bui AN 

PROVIDER: S-EPMC9153254 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature